Back to GetFilings.com



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

For the Quarterly Period Ended March 31, 2004

 

Commission File Number 0-18044

 

PROCYTE CORPORATION

(Exact name of the registrant as specified in its charter)

 

Washington

 

91-1307460

(State of incorporation)

 

(I.R.S. Employer Identification No.)

 

 

 

8511 154th Avenue N.E., Redmond, WA

 

98052

(Address of principal executive offices)

 

(Zip code)

 

 

 

Registrant’s telephone number, including area code:

 

(425) 869-1239

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ý

 

No o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).

 

Yes o

 

No ý

 

As of April 30, 2004, there were issued and outstanding 15,798,747 shares of common stock, par value $.01 per share.

 

 



 

ProCyte Corporation

 

Index

 

Part I - Financial Information

 

 

Item 1. Condensed Consolidated Financial Statements (unaudited)

 

 

 

Balance Sheets - as of March 31, 2004 and December 31, 2003 (unaudited)

 

 

 

Statements of Operations - Three Months Ended March 31, 2004 and 2003 (unaudited)

 

 

 

Statements of Cash Flows – Three Months Ended March 31, 2004 and 2003 (unaudited)

 

 

 

Statements of Stockholders’ Equity – Three Months Ended March 31, 2004 (unaudited)

 

 

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

 

Item 4. Controls and Procedures

 

Part II - Other Information

 

 

Item 1. Legal Proceedings

 

 

Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

 

 

Item 3. Defaults Upon Senior Securities

 

 

Item 4. Submission of Matters to a Vote of Security Holders

 

 

Item 5. Other Information

 

 

Item 6. Exhibits and Reports on Form 8-K

 

Signatures

 

 

2



 

Part I - Financial Information

 

Item 1. Condensed Consolidated Financial Statements (unaudited)

 

Balance Sheets - as of March 31, 2004 and December 31, 2003 (unaudited)

(in thousands)

 

 

 

March 31, 2004

 

December 31,
2003

 

ASSETS

 

 

 

 

 

Current Assets

 

 

 

 

 

Cash and cash equivalents

 

$

4,371

 

$

3,796

 

Accounts receivable, net of allowance for doubtful accounts

 

1,516

 

1,336

 

Inventory

 

2,594

 

2,942

 

Prepaid and Other

 

230

 

289

 

Total current assets

 

8,711

 

8,363

 

 

 

 

 

 

 

Property and equipment

 

 

 

 

 

Equipment

 

322

 

315

 

Leasehold improvements

 

3,520

 

3,520

 

Less accumulated depreciation and amortization

 

(3,337

)

(3,294

)

Property and equipment, net

 

505

 

541

 

 

 

 

 

 

 

Intangible assets

 

3,212

 

3,212

 

Note due from related party, net

 

781

 

781

 

Deferred tax asset

 

7,042

 

7,068

 

Other assets

 

38

 

38

 

Total Assets

 

$

20,289

 

$

20,003

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current Liabilities

 

 

 

 

 

Accounts payable, trade

 

$

509

 

$

147

 

Accrued salaries and benefits

 

206

 

246

 

Other accrued liabilities

 

182

 

239

 

Deferred revenue

 

16

 

60

 

Total current liabilities

 

913

 

692

 

Other liabilities

 

93

 

93

 

Total Liabilities

 

1,006

 

785

 

Stockholders’ Equity

 

 

 

 

 

Common stock and additional paid-in-capital

 

85,434

 

85,419

 

Deferred compensation

 

(59

)

(59

)

Accumulated deficit

 

(66,092

)

(66,142

)

Stockholders’ Equity

 

19,283

 

19,218

 

Total Liabilities and Stockholders’ Equity

 

$

20,289

 

$

20,003

 

 

See notes to condensed consolidated financial statements

 

3



 

Statements of Operations - Three Months Ended March 31, 2004 and 2003 (unaudited)

(in thousands, except per share amounts)

 

 

 

Three months ended March 31,

 

 

 

2004

 

2003

 

Revenues

 

 

 

 

 

Product sales

 

$

2,861

 

$

2,882

 

Licenses and royalties

 

359

 

464

 

Total revenues

 

3,220

 

3,346

 

Cost of product sales

 

861

 

1,183

 

Gross profit

 

2,359

 

2,163

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

Marketing and selling

 

1,198

 

1,400

 

Research, general, and administrative

 

1,091

 

966

 

Total operating expenses

 

2,289

 

2,366

 

 

 

 

 

 

 

Operating income (loss)

 

70

 

(203

)

Interest and other income

 

7

 

88

 

 

 

 

 

 

 

Net income before tax

 

77

 

(115

)

Provision for income tax

 

(27

)

(18

)

Net income (loss)

 

$

50

 

$

(133

)

 

 

 

 

 

 

Net earnings (loss) per share

 

 

 

 

 

Basic

 

$

0.00

 

$

(0.01

)

Diluted

 

$

0.00

 

$

(0.01

)

 

 

 

 

 

 

Shares used in per share computation

 

 

 

 

 

Basic

 

15,790

 

15,746

 

Diluted

 

16,048